Development of safety prediction biomarker for drug eluting coronary stent therapy

2018 Fiscal Year Final Research Report

• Project/Area Number: 17K19688
• Research Category: Grant-in-Aid for Challenging Research (Exploratory)
• Allocation Type: Multi-year Fund
• Research Field: Internal medicine of the bio-information integration and related fields
• Research Institution: Jichi Medical University
• Principal Investigator: FUJIMURA Akio 自治医科大学, 医学部, 客員教授 (90156901)
• Co-Investigator(Kenkyū-buntansha): 相澤 健一 自治医科大学, 医学部, 准教授 (70436484)
• Project Period (FY): 2017-06-30 – 2019-03-31
• Keywords: 応用薬理学

Outline of Final Research Achievements

In cardiac catheterization widely used for the treatment of coronary artery stenosis, restenosis is still observed in about 10% of cases still in the heyday of coronary artery drug-eluting stents. This is one of the limitations of interventional therapy, and the development of biomarkers that can be used for diagnostic as well as predictive support is urgently needed. In this study, we will develop new safety prediction biomarkers for drug-eluting coronary stent treatment. Blood was collected after consent was obtained from a patient admitted to the Department of Cardiology, Jichi Medical University Hospital. Metabolomic analysis was performed to identify 14 compounds (high or low relative to control) that varied specifically in restenosis cases.

Free Research Field

生体情報内科学およびその関連分野

Academic Significance and Societal Importance of the Research Achievements

狭心症の治療法として実施されている心臓カテーテル治療では、冠動脈薬剤溶出ステントが広く普及したが、現在でも未だ１割以上の症例では、カテーテルで広げた血管が再び狭くなる再狭窄が認められる。これはインターベンション療法の限界の一つであり、診断ならびに予測支援に用いることが可能なバイオマーカーの開発は急務である。本研究では最新のメタボローム解析法を用いて、再狭窄例に特異的に変動した14化合物を同定した。これらは、狭心症の診断ならびにカテーテル治療後の予後予測支援への応用が期待される。